-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]
San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]
- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships – [...]
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]
San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., (Forge) announced today that the company will present a talk entitled, “Forging new [...]
San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data [...]
San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the [...]
San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]
SAN DIEGO, California, June 12, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]
San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]
